Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus trastuzumab and chemotherapy in HER2-positive metastatic gastric or gastroesophageal junction cancer
jRCT2080222112Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pertuzumab arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Started Jun 2013; status: completed.
02
Drugs
pertuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222112.